Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | -5.36% | +3.92% | +92.73% |
May. 14 | Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
Financials (USD)
Sales 2024 * | 30M | Sales 2025 * | 18.75M | Capitalization | 39.13M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -70M | EV / Sales 2024 * | -5.25 x |
Net cash position 2024 * | 196M | Net cash position 2025 * | 302M | EV / Sales 2025 * | -14 x |
P/E ratio 2024 * |
-1.68
x | P/E ratio 2025 * |
-0.89
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.21% |
Latest transcript on Xilio Therapeutics, Inc.
1 day | -5.36% | ||
1 week | +3.92% | ||
Current month | -1.85% | ||
1 month | -10.17% | ||
3 months | +58.09% | ||
6 months | +51.39% | ||
Current year | +92.73% |
Managers | Title | Age | Since |
---|---|---|---|
René Russo
CEO | Chief Executive Officer | 49 | 19-05-21 |
Kevin Brennan
DFI | Director of Finance/CFO | 54 | - |
Chief Tech/Sci/R&D Officer | - | 22-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Clancy
CHM | Chairman | 62 | 20-07-22 |
Daniel Curran
BRD | Director/Board Member | 57 | 20-11-30 |
Tomas Jan Heyman
BRD | Director/Board Member | 68 | 22-09-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 1.06 | -5.36% | 143,781 |
24-06-11 | 1.12 | +5.66% | 113,232 |
24-06-10 | 1.06 | +0.95% | 154,359 |
24-06-07 | 1.05 | +2.94% | 7,175,939 |
24-06-06 | 1.02 | 0.00% | 103,113 |
Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.73% | 39.13M | |
+48.54% | 56.61B | |
+37.15% | 39.25B | |
-6.02% | 39.62B | |
-6.90% | 28.28B | |
+12.97% | 26.44B | |
-16.91% | 20.12B | |
+31.71% | 12.48B | |
+28.18% | 12.51B | |
+0.38% | 12.2B |
- Stock Market
- Equities
- XLO Stock